See our full publication list Publications
- Bernatchez, J. A.; Coste, M.; Beck, S.; Wells, G. S.; Luna, L. A.; Clark, A. E.; Zhu, Z.; Sohl, C. D.*; Purse, B. W.*; Siqueira-Neto, J. L.* (2019) Viruses, in press. “Activity of selected nucleoside analogue ProTides against Zika virus in human neural stem cells.” (*co-corresponding authors).
- Kennedy, M. A.; Xu, Z.; Wu, Y.; and Sohl, C. D. (2019) Biochem Biophys Res Commun 509, 898-902. A Tie2 kinase mutation causing venous malformations increases phosphorylation rates and enhances cooperativity. PMID:30638931
- Ryan, M. R.; Sohl, C. D.; Luo, B.; and Anderson, K. A. (2019) Mol Cancer Res 17, 532-543. The FGFR1 V561M gatekeeper mutation drives AZD4547 resistance through STAT3 activation and EMT. PMID30257990.
- Matteo, D. A.; Wells, G. A.; Luna, L. A.; Grunseth, A. J.; Zagnitko, O.; Scott, D. A.; Hoang, A.; Luthra, A.; Swairjo, M. A.; Schiffer, J. A.; and Sohl, C. D. (2018) Biochem J 475, 3221-3238. Inhibitor potency varies widely among tumor relevant human isocitrate dehydrogenase 1 mutants. PMID30257990
- Bernatchez, J. A., Coste, Yang, Z., Coste, M., Li, J., Beck, S., Liu, Y., Clark, A. E., Zhu, Z., Luna, L. A., Sohl, C. D., Purse, B. W., Li, R., and Siqueira-Neto, J. L. (2018) Antimicrob Agents Chemother 62, e00725-18. “Development of a phenotypic high-content imaging assay for assessing the antiviral activity of small-molecule inhibitors targeting the Zika virus.” PMID30257990.
- Matteo, D. M.*, Grunseth, A. J.*, Gonzalez, E. R., Anselmo, S. L., Kennedy, M. A., Moman, P., Scott, D. A., Hoang, A., and Sohl, C. D. (2017) J Biol Chem 292, 7971-83. “Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: the role of size and hydrophobicity at residue 132 on catalytic efficiency.” (*co-first author). PMID:28330869
- Sohl, C. D., Ryan, M. R., Luo, B., Frey, K. M., and Anderson, K. S. (2015) ACS Chem Biol 10, 1319-29. “Illuminating the molecular mechanism of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles’ heel of targeted therapy.”
- Sohl, C. D.*, Szymanski, M. R.*, Mislak, A. C., Shumate, C. K., Amiralaei, S., Schinazi, R. F., Anderson, K. S., and Yin, Y. W. (2015) Proc Natl Acad Sci USA 112, 8596-601. “Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase g.” (*co-first author).
- Sohl, C. D.*, Ray, S., and Sweasy, J. B. (2015) Proc Natl Acad Sci USA 112, 5864-5. “Pools and pols: mechanism of a mutator phenotype. (*co-first author)
- Towle-Weicksel, J. B., Dalal, S., Sohl, C. D., Doublie, S., Anderson, K. S., Sweasy, J. B. (2014) J Biol Chem 289, 16541-50. “Fluorescence resonance energy transfer studies of DNA polymerase ß: the critical role of fingers domain movements and a novel non-covalent step during nucleotide selection.”
- Muftuoglu, Y.*, Sohl, C. D.*, Mislak, A. C., Mitsuya, H., Sarafianos, S. G., and Anderson, K. S. (2014) Antiviral Res 106, 1-4. “Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4’-ethynyl-2-fluoro-2’-deoxyadenosine (EFdA) using pre-steady-state kinetics.” (*co-first author)
- Sohl, C. D., Kasiviswanathan, R., Copeland, W. C., and Anderson, K. S. (2013) Hum Mol Genet 22, 1074-85. “Mutations in human DNA polymerase g confer unique mechanisms of catalytic deficiency that mirror the disease severity in mitochondrial disorder patients.”
- Cheng, Q., Sohl, C. D., Yoshimoto, F. K., and Guengerich, F. P. (2012) J Biol Chem 287, 59554-67. “Oxidation of dihydrotestosterone by human cytochromes P450s 19A1 and 3A4.”
- Sohl, C. D., Kasiviswanathan, R., Kim, J., Pradere, U., Schinazi, R. F., Copeland, W. C., Mitsuya, H., Baba, M., and Anderson, K. (2012) Mol Pharmacol 82, 125-33. “Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.”
- Sohl, C. D., Singh, K., Kasiviswanathan, R., Copeland, W. C., Mitsuya, H., Sarafianos, S., and Anderson, K. (2012) Antimicrob Agents Chemother 56, 1630-4. “Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4’-ethynyl-2-fluoro-2’-deoxyadenosine indicates a low potential for host toxicity.”
- Guengerich, F. P., Sohl, C. D., and Chowdhury, G. (2011) Arch Biochem Biophys 507, 126-34. “Multi-step oxidations catalyzed by cytochrome P450 enzymes: processive distributive kinetics and the issue of carbonyl oxidation in chemical mechanisms.”
- Sohl, C. D., and Guengerich, F. P. (2010) J Biol Chem 285, 17734-17743. “Kinetic analysis of the three-step steroid aromatase reaction of human cytochrome P450 19A1.”
- Cheng, Q., Sohl, C. D., and Guengerich, F. P., (2009) Nat Protoc 4, 1258-61. “High-throughput fluorescence assay of cytochrome P450 3A4.”
- Sohl, C. D., Cheng, Q., and Guengerich, F. P. (2009) Nat Protoc 4, 1252-7. “Chromatographic assays of drug oxidation by human cytochrome P450 3A4.”
- Guengerich, F. P., Martin, M. V., Sohl, C. D., and Cheng, Q. (2009) Nat Protoc 4, 1245-51. “Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase.”
- Sohl, C. D., Isin, E. M., Eoff, R. L., Marsch, G. A., Stec, D. F., and Guengerich, F. P. (2008) J Biol Chem 283, 7293-7308. “Cooperativity in oxidation reactions catalyzed by cytochrome P450 1A2. Highly cooperative pyrene hydroxylation and multiphasic kinetics of ligand binding.”
- Isin, E. M.*, Sohl, C. D.*, Eoff, R. L., and Guengerich, F. P. (2008) Arch Biochem Biophys 473, 69-75. “Cooperativity of cytochrome P450 1A2: interaction of 1,4-phenylene diisocyanide and 1-alkoxy-4-nitrobenzenes.” (*co-first author)
- Wu, Z-L., Sohl, C. D., Shimada, T., and Guengerich, F. P. (2006) Mol Pharmacol 69, 2007-2014. “Recombinant enzymes over-expressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1.”
- Sohl, C. D., Lee, J., Alguindigue, S. S., Khan, M. A., and Richter-Addo, G. B. (2004) J Inorg Biochem 98, 1238-46. “Synthesis and solid-state molecular structures of nitrosoalkane complexes of iron porphyrins containing methanol, pyridine, and 1-methylimidazole ligands.”